SFM
MDGL icon

Sphera Funds Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sphera Funds Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,857
Closed -$524K – 128
2013
Q4 		$524K Buy
+2,857
New +$523K 0.15% 91

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's MDGL Position: Q1 2026 in Review

Sphera Funds Management increased its Madrigal Pharmaceuticals (MDGL) stake by 174% in Q1 2026, buying an estimated $2.74M and bringing the position to 9,040 shares worth $4.73M. The position accounts for 0.75% of the portfolio, ranked #49.

Sphera Funds Management first reported a position in MDGL in Q1 2023 and has held it in 6 quarters since. The position peaked at $7.43M in Q3 2023. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Sphera Funds Management held 9,040 shares of Madrigal Pharmaceuticals worth $4.73M as of Q1 2026.
  • Sphera Funds Management bought 5,740 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $2.74M.
  • Madrigal Pharmaceuticals made up 0.75% of Sphera Funds Management's portfolio in Q1 2026, its #49 holding.
  • Sphera Funds Management first reported a position in Madrigal Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • Sphera Funds Management's Madrigal Pharmaceuticals position peaked at $7.43M in Q3 2023.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.